This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents *will not* correct images, please do not report the images to the Image Problems Mailbox.

Refine Search

Search Results -

Terms	Documents
succinimide.ti.	1255

Database: US Pre-Grant Publication Full-Text Database; US Patents Full-Text Database; US OCR Full-Text Database; EPO Abstracts Database; JPO Abstracts Database; Derwent World Patents Index; IBM Technical Disclosure Bulletins

Search: L8 and (cancer or prostate)

Refine Search | Recall Text | Clear | Interrupt

Search History

DATE: Tuesday, December 30, 2003 Printable Copy Create Case

Set Name side by side	Query	Hit Count	Set Name result set
DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI; PLUR=YES; OP=AND			
L8	succinimide.ti.	1255	L8
L7	succinimide near fused	1	L7
L6	succinimide near fused	1	L6
L5	succinimide	19480	L5
DB=USPT; PLUR=YES; OP=AND			
L4	L3 and (cancer or prostate)	96	L4
L3	l1 and succinimide	386	L3
L2	L1 and prostate adj cancer	164	L2
L1	(514/408-448)![CCLS]	9275	L1

END OF SEARCH HISTORY

```
=> d hist

     (FILE 'HOME' ENTERED AT 10:13:09 ON 30 DEC 2003)

     FILE 'REGISTRY' ENTERED AT 10:13:15 ON 30 DEC 2003
L1                STRUCTURE UPLOADED
L2              0 S SAM L1
L3                STRUCTURE UPLOADED
L4             29 S SAM L3
L5           2157 S FULL L3

     FILE 'CAPLUS' ENTERED AT 10:18:33 ON 30 DEC 2003
L6            617 S L5
L7              3 S L6 AND CANCER

     FILE 'REGISTRY' ENTERED AT 10:22:32 ON 30 DEC 2003
L8                STRUCTURE UPLOADED
L9             50 S SAM L8
L10          6697 S FULL L8

     FILE 'CAPLUS' ENTERED AT 10:24:20 ON 30 DEC 2003
L11          2857 S L10
L12            11 S L11 AND CANCER
L13            10 S L12 NOT L7
L14             5 S L11 AND PROSTAT?
L15             4 S L14 NOT L12
L16             1 S L14 AND L12

=> s l6 and prostat?
         36032 PROSTAT?
L17              2 L6 AND PROSTAT?

=> s l17 not l7
L18              1 L17 NOT L7
```

Refine Search

Search Results -

Terms	Documents
succinimide.ti.	1255

Database: US Pre-Grant Publication Full-Text Database; US Patents Full-Text Database; US OCR Full-Text Database; EPO Abstracts Database; JPO Abstracts Database; Derwent World Patents Index; IBM Technical Disclosure Bulletins

Search: L8 and (cancer or prostate)

Refine Search | Recall Text | Clear | Interrupt

Search History

DATE: Tuesday, December 30, 2003 Printable Copy Create Case

Set Name side by side	Query	Hit Count	Set Name result set
DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI; PLUR=YES; OP=AND			
L8	succinimide.ti.	1255	L8
L7	succinimide near fused	1	L7
L6	succinimide near fused	1	L6
L5	succinimide	19480	L5
DB=USPT; PLUR=YES; OP=AND			
L4	L3 and (cancer or prostate)	96	L4
L3	l1 and succinimide	386	L3
L2	L1 and prostate adj cancer	164	L2
L1	(514/408-448)![CCLS]	9275	L1

END OF SEARCH HISTORY

ANSWER 2 OF 3 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2002:675838 CAPLUS
DOCUMENT NUMBER: 137:216934
TITLE: Preparation of fused cyclic succinimide compounds and analogs thereof, as modulators of nuclear hormone receptor function
INVENTOR(S): Salvati, Mark E.; Attar, Ricardo M.; Gottardis, Marco M.; Balog, James A.; Pickering, Dacia A.; Martinez, Rogelio L.; Sun, Chongqing
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
SOURCE: PCT Int. Appl., 331 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002067939	A1	20020906	WO 2002-US5302	20020220

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2001-271672P P 20010227
OTHER SOURCE(S): MARPAT 137:216934
GI



I



II

AB Title compds. I [G = (un)substituted cycloalkenyl, aryl or heterocyclo (mono or polycyclic); Z1 and Z2 independently = O, S, NH or substituted amine; L = bond, substituted alkyl chain, NH, substituted amine; A1 and A2 independently = CR1 or N when Y = J-J'-J'' where J = (CR1R1')n with n = 0-3, J' = bond, carbonyl, CR1R1', R2P:O, R2P:S, etc., and W = CR1R1'-CR1R1', CR3:CR3', (un)substituted cycloalkyl, etc.; or when Y is

absent A1 and A2 independently = CR1R1' or NR1; or when Y is absent A1, A2 and W together form -NR1-N:N-; Q1 and Q2 independently = H, (un)substituted alkyl, alkenyl, cycloalkyl, etc.; R1 and R1' independently = H, (un)substituted alkyl, alkenyl, cycloalkyl, cycloalkenyl, amino, halo, CN, etc.; R2 = (un)substituted alkyl, cycloalkyl, cycloalkenyl, heterocyclo, aryl, arylalkyl, etc.; R3 and R3' independently = H, (un)substituted alkyl, alkenyl, CN, halo, nitro, amino, etc.] are prepd. and methods of using such compds. in the treatment of nuclear hormone receptor-assocd. conditions; and pharmaceutical compns. contg. such compds are disclosed. Thus, II was prepd. by cyclocondensation of (3a.alpha.,4.beta.,8.beta.,8a.alpha.)-4,5,6,7,8,8a-hexahydro-4,8-etheno-1H-cyclohepta[c]furan-1,3(3aH)dione (prepn. given) with 3-(trifluoromethyl)aniline. Combinatorial methods of prepg. compds. of formula I are also provided. As modulators of nuclear hormone receptor function, the use of I as potential anticancer agents and for treatment of immune disorders is claimed (no data).

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2003:511091 CAPLUS
DN 139:85335
TI Preparation of fused heterocyclic compounds and analogs thereof as modulators of nuclear hormone receptor function
IN Salvati, Mark E.; Balog, James Aaron; Pickering, Dacia A.; Zhu, Hong
PA Bristol-Myers Squibb Company, USA
SO PCT Int. Appl., 147 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003053358	A2	20030703	WO 2002-US40737	20021218
	WO 2003053358	A3	20031002		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2003181728	A1	20030925	US 2002-322276	20021218
PRAI	US 2001-341962P	P	20011219		

OS MARPAT 139:85335

L13 ANSWER 9 OF 10 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 1999:421667 CAPLUS
DOCUMENT NUMBER: 131:58659
TITLE: Preparation of diaryl ureas as inhibitors of p38 kinase.
INVENTOR(S): Miller, Scott; Osterhout, Martin; Dumas, Jacques; Khire, Uday; Lowinger, Timothy Bruno; Riedl, Bernd; Scott, William J.; Smith, Roger A.; Wood, Jill E.; Gunn, David; Hatoum-Mokdad, Holia; Rodriguez, Mareli; Sibley, Robert; Wang, Ming
PATENT ASSIGNEE(S): Bayer Corporation, USA
SOURCE: PCT Int. Appl., 107 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9932463	A1	19990701	WO 1998-US27265	19981222
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2315715	AA	19990701	CA 1998-2315715	19981222
AU 9919399	A1	19990712	AU 1999-19399	19981222
EP 1042305	A1	20001011	EP 1998-964221	19981222
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2001526276	T2	20011218	JP 2000-525400	19981222

PRIORITY APPLN. INFO.: US 1997-995749 A 19971222
WO 1998-US27265 W 19981222

OTHER SOURCE(S): MARPAT 131:58659

AB A method of treating a p-38 mediated disease other than **cancer** comprises administration of BNHCONHA [A = (substituted) Ph, pyridyl, 2-thienyl; B = (substituted) aryl, heteroaryl contg. .gtoreq.1 6-membered arom. structure contg. 0-4 N, O, or S atoms]. Thus, 5-tert-butyl-2-(3-tetrahydrofuranyloxy)aniline (prepn. given) and p-tolyl isocyanate were stirred 8 h in PhMe to give 75% N-(5-tert-butyl-2-(3-tetrahydrofuranyloxy)phenyl)-N'-(4-methylphenyl)urea. Title compds. inhibited p38 kinase with IC50 = 1-10 .mu.M.

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 1999:244628 CAPLUS
DOCUMENT NUMBER: 130:296612
TITLE: Preparation of amidocarboxylic acid derivatives as inhibitors of aldose reductase, 5-lipoxygenase, and lipid peroxide formation and as peroxisome proliferator-activated receptor (PPAR) activators
INVENTOR(S): Yanagisawa, Hiroaki; Sakurai, Mitsuya; Takamura, Makoto; Fujiwara, Toshihiko
PATENT ASSIGNEE(S): Sankyo Company, Ltd., Japan
SOURCE: PCT Int. Appl., 720 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9918066	A1	19990415	WO 1998-JP4396	19980930
W: AU, BR, CA, CN, CZ, HU, ID, IL, JP, KR, MX, NO, NZ, PL, RU, TR, US				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2305808	AA	19990415	CA 1998-2305808	19980930
AU 9892798	A1	19990427	AU 1998-92798	19980930
AU 738134	B2	20010906		
EP 1026149	A1	20000809	EP 1998-945527	19980930
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
BR 9813019	A	20000905	BR 1998-13019	19980930
RU 2176999	C2	20011220	RU 2000-108440	19980930
US 6528525	B1	20030304	US 2000-540765	20000330
NO 2000001689	A	20000531	NO 2000-1689	20000331

PRIORITY APPLN. INFO.: JP 1997-269923 A 19971002
WO 1998-JP4396 W 19980930
OTHER SOURCE(S): MARPAT 130:296612
GI



I



II

AB Claimed and prepd. are amidocarboxylic acid derivs. (phenylalkanoic acids contg. arylcarboxamide derivs.) represented by general formula (I), pharmacol. acceptable salts thereof, or pharmacol. acceptable esters

thereof, [wherein R1 = H, linear or branched C1-6 alkyl, C7-12 aralkyl; R2 = linear or branched C1-6 alkylene; R3 = H, linear or branched alkyl C1-6 alkyl, C1-4 alkoxy, or C1-4 alkylthio, halo, NO2, di(linear or branched C1-4 alkyl)amino, (un)substituted C6-10 aryl, C7-12 aralkyl optionally having 1-5 substituents on the aryl, OH, linear or branched C1-5 aliph. acyl; R4 = H, linear or branched C1-6 alkyl; Z = linear or branched C1-6 alkylene; W = HO, linear or branched C1-6 alkyl, C1-4 alkoxy, or C1-4 alkylthio, (un)substituted C6-10 aryl, C6-10 aryloxy, C6-10 arylthio, C7-12 aralkyloxy, C7-12 aralkylthio, or C6-10 aryloxy-linear or branched C1-4 alkyl each optionally having 1-5 substituents on the aryl, 5- to 10-membered mono- or bicyclic heteroaryloxy contg. 1-4 heteroatoms selected from O, N, and S, etc.; X = C6-10 aryl optionally having 1-3 substituents, 5- to 10-membered mono- or bicyclic heteroaryl contg. 1-4 heteroatoms selected from O, N, and S; Y = single bond, O, S, (un)substituted NH]. Also claimed are blood sugar- and blood lipid-lowering agents, insulin resistance improver, antiinflammatory agents, immunomodulators, aldose reductase inhibitors, 5-lipoxygenase inhibitors, lipid peroxide formation inhibitors, PPAR activators, and anti-osteoporosis agents and therapeutic or prophylactic agents for diabetes, hyperlipemia, obesity, impaired glucose tolerance, insulin resistant non-impaired glucose tolerance, fatty liver, diabetes complications, gestational diabetes mellitus, polycystic ovary syndrome, osteoarthritis, rheumatoid arthritis, allergies, asthma, **cancers**, autoimmune diseases, pancreatitis, and cataract. Thus, N-deprotection of Et 2-ethoxy-3-[4-(2-phthalimidoethoxy)phenyl]propionate with hydrazine hydrate in MeOH at room temp. for 1.5 h followed by amidation with 4-pyridin-2-ylbenzoic acid using carbonyl diimidazole in CH2Cl2 at room temp. for 1. 5 h followed by sapon. with a mixt. of 1 N aq. NaOH and MeOH and acidification gave 3-[4-[2-(4-pyridin-2-ylbenzoylamino)ethoxy]phenyl]propionic acid deriv. (II.Na; R = H, R1 = Et) (III). III and (S)-II (R = H, R1 = 4-isopropoxyphenyl) in feed contg. 0.01% at .apprx.10 mg drug/kg/day for 3 days lowered blood sugar level by 43 and 73%, resp. A capsule, a tablet, and a granule formulation contg. III were prepd.

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2003:922571 CAPLUS
DOCUMENT NUMBER: 139:375043
TITLE: Tandospirone and buspirone and their salts as analgesics for neurogenic pain
INVENTOR(S): Ono, Yukihiro; Soeda, Hiroko
PATENT ASSIGNEE(S): Sumitomo Pharmaceutical Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 3 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2003335678	A2	20031125	JP 2002-143706	20020517

PRIORITY APPLN. INFO.: JP 2002-143706 20020517

AB Tandospirone and buspirone and their salts are claimed as analgesics for neurogenic pain, e.g. from surgery, diabetic neuropathy, herpes, sympathetic nerve atrophy, **cancer**, etc.